nirmatrelvir (Paxlovid) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C
  • InChIKey: LIENCHBZNNMNKG-OJFNHCPVSA-N
  • Mol. Mass: 499.53
  • ALogP: 1.1
  • ChEMBL Molecule:
    nirmatrelvir  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( ritonavir (Norvir), nirmatrelvir (Paxlovid) - other name: nirmatrelvir and ritonavir )

Organizations (33)

Research & Development (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

COVID-19

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Biological Availability (Phase 1)

Child, Hospitalized (Phase 2)

COVID-19 (Phase 4)

Healthy Volunteers (Phase 1)

Hospitalization (Phase 2)

Immunocompromised Host (Phase 2)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Mesenchymal Stem Cells (Phase 3)

Pharmacokinetics (Phase 1)

Post-Acute COVID-19 Syndrome (Phase 3)

Primary Immunodeficiency Diseases (Phase 2/Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Thoracic Surgery (Phase 4)

Uremia (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial Organizations: 33

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue